经眼动脉介入化学疗法治疗视网膜母细胞瘤的研究进展

经眼动脉介入化学药物治疗（intra-arterial chemotherapy，IAC）是通过介入的方法从眼动脉向患眼注射化学治疗（化疗）药物，对视网膜母细胞瘤（retinoblastoma，RB）进行局部化疗的一种治疗方法。目前IAC治疗RB的常用药物有美法仑、拓扑替康和卡铂。经眼动脉注射化疗药物，可在局部形成高浓度药物作用，有效杀伤肿瘤细胞，同时可显著降低静脉化疗全身并发症的发生率。应用IAC治疗RB国际分期中B、C、D期及部分E期患者，可有效提高保眼率。IAC的主要并发症包括眼睑、结膜水肿，眼睑下垂，眼球运动障碍，玻璃体出血，视网膜、脉络膜缺血和一过性骨髓抑制等。目前，IAC技术已在国际上广泛开展，本文主要对其临床应用研究进行综述。

Intra-arterial chemotherapy for the treatment of retinoblastoma

Intra-arterial chemotherapy (IAC) refers to the injection of chemotherapeutics into patients’ eyes through arteria ophthalmica in order to local chemotherapy for retinoblastoma (RB).The common drugs in the treatment of RB include melphalan，topotecan and carboplatin.IAC can form the high-concentration drug effects on local areas.It can effectively kill tumors and significantly reduce the occurrence rate of complications after intravenous chemotherapy.Application of IAC can cure patients with RB in B，C，D and E stage in international criteria，which can effectively improve eye protection rate.Complications of IAC include eyelids edema，chemosis，blepharoptosis，ocular motility disorders，vitreous hemorrhage，ischemia of choroid or retina，transient myelosuppression，etc.It should be further conduction of long-term and large-sample cases studies on how to improve curative effects and reduce serious eye complications.